Willemijn Hobo

12PUBLICATIONS
45CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsHaematological tumoursTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Sep 20, 2023
Human CD34+-derived complete plasmacytoid and conventional dendritic cell vaccine effectively induces antigen-specific CD8+ T cell and NK cell responses in vitro and in vivo.

Jesper van Eck van der Sluijs, Diede van Ens, Jolanda Brummelman

|Oct 07, 2021
CD34+ progenitor-derived NK cell and gemcitabine combination therapy increases killing of ovarian cancer cells in NOD/SCID/IL2Rgnull mice.

Jolien M R Van der Meer, Paul K J D de Jonge, Anniek B van der Waart

|Sep 15, 2021
Correction to: IL‑15 superagonist N‑803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor‑derived NK cells.

J M R Van der Meer, R J A Maas, K Guldevall

|Apr 02, 2021
Clinically applicable CD34+-derived blood dendritic cell subsets exhibit key subset-specific features and potently boost anti-tumor T and NK cell responses.

Jesper van Eck van der Sluijs, Diede van Ens, Soley Thordardottir

|Nov 23, 2020
TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer.

Ralph Ja Maas, Janneke S Hoogstad-van Evert, Jolien Mr Van der Meer

|Nov 03, 2020
IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor-derived NK cells.

J M R Van der Meer, R J A Maas, K Guldevall

Pageof 2

Frequent Collaborators

9 joint publications

Anniek B van der Waart

9 joint publications

Harry Dolstra

9 joint publications

Nicolaas Schaap

8 joint publications

Joop H Jansen